{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T05:38:01Z","timestamp":1777873081507,"version":"3.51.4"},"reference-count":39,"publisher":"Frontiers Media SA","issue":"1","license":[{"start":{"date-parts":[[2017,11,2]],"date-time":"2017-11-02T00:00:00Z","timestamp":1509580800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Exp Biol Med (Maywood)"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:p>\n                    Bone cancer pain (BCP) is a severe type of hyperpathic pain occurring with primary bone tumors or advanced cancers which metastasize to bones. BCP can detrimentally reduce quality of life and presents a challenge to modern medicine. Studies have shown that exogenous H\n                    <jats:sub>2<\/jats:sub>\n                    S may act as a neuroprotectant to protect against some diseases in central nervous system. The preset study aimed to investigate the antinociceptive effect of H\n                    <jats:sub>2<\/jats:sub>\n                    S in BCP. We first measured the changes of serum H\n                    <jats:sub>2<\/jats:sub>\n                    S in patients with BCP and analyzed the relationship between them, then investigated the effect of H\n                    <jats:sub>2<\/jats:sub>\n                    S preconditioning on BCP, and explored the mechanism in rat model. Our results revealed that serum H\n                    <jats:sub>2<\/jats:sub>\n                    S level was negatively correlated with pain scores. In the rat model of BCP, preconditioning with H\n                    <jats:sub>2<\/jats:sub>\n                    S significantly reduced BCP, demonstrated by the decrease of thermal hyperalgesia and mechanical allodynia. The mechanism of H\n                    <jats:sub>2<\/jats:sub>\n                    S preconditioning may involve microglia deactivation and inflammation inhibition in the spinal cord, in which the proliferator-activated receptor gamma\/p38\/Jun N-terminal kinase pathway is activated.\n                  <\/jats:p>\n                  <jats:sec>\n                    <jats:title>Impact statement<\/jats:title>\n                    <jats:p>\n                      Bone cancer pain (BCP) significantly decreases the life quality of patients or their life expectancy and causes a severe health burden to the society. However, as the exact mechanism of BCP is still poorly understood, no effective treatment has been developed yet. There are some pain medicines now, but they have some inevitable side effects. Additional therapeutic strategies are urgently needed. First, we revealed that preconditioning with H\n                      <jats:sub>2<\/jats:sub>\n                      S significantly reduced BCP, demonstrated by the decrease of thermal hyperalgesia and mechanical allodynia. Second, the mechanism of H\n                      <jats:sub>2<\/jats:sub>\n                      S preconditioning was elucidated. It may involve microglia deactivation and inflammation inhibition in the spinal cord, in which the proliferator-activated receptor gamma\/p38\/Jun N-terminal kinase pathway is activated. This novel finding may significantly help us to understand the difference between the roles of endogenous H\n                      <jats:sub>2<\/jats:sub>\n                      S and exogenous H\n                      <jats:sub>2<\/jats:sub>\n                      S in the development of BCP and present us a new strategy of pain management.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1535370217740859","type":"journal-article","created":{"date-parts":[[2017,11,3]],"date-time":"2017-11-03T09:41:55Z","timestamp":1509702115000},"page":"57-65","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Preconditioning with hydrogen sulfide prevents bone cancer pain in rats through a proliferator-activated receptor gamma\/p38\/Jun N-terminal kinase pathway"],"prefix":"10.3389","volume":"243","author":[{"given":"Li","family":"Zhuang","sequence":"first","affiliation":[{"name":"The Department of Palliative Medicine, The Third Affiliated Hospital of Kunming Medical University, Yunnan Tumor Hospital, Yunnan Palliative Medicine Research Center, Yunnan 650118, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Li","sequence":"additional","affiliation":[{"name":"The Second Department of Medicine, the Third Affiliated Hospital of Kunming Medical University, Yunnan Tumor Hospital, Yunnan 650118, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaowei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Service, the Third Affiliated Hospital of Kunming Medical University, Yunnan Tumor Hospital, Yunnan 650118, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Shou","sequence":"additional","affiliation":[{"name":"Department of Oncology, the First People\u2019s Hospital of Yunnan Province, Yunnan 650032, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunlin","family":"Gao","sequence":"additional","affiliation":[{"name":"The Second Department of Medicine, the Third Affiliated Hospital of Kunming Medical University, Yunnan Tumor Hospital, Yunnan 650118, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Pain Medicine, the Third Affiliated Hospital of Kunming Medical University, Yunnan Tumor Hospital, Yunnan 650118, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingliang","family":"Bao","sequence":"additional","affiliation":[{"name":"The Second Department of Medicine, the Third Affiliated Hospital of Kunming Medical University, Yunnan Tumor Hospital, Yunnan 650118, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingli","family":"Zhao","sequence":"additional","affiliation":[{"name":"The Third Department of Medicine, the Third Affiliated Hospital of Kunming Medical University Yunnan Tumor Hospital, Yunnan 650118, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2017,11,2]]},"reference":[{"key":"bibr1-1535370217740859","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2017.04.017"},{"key":"bibr2-1535370217740859","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000000848"},{"key":"bibr3-1535370217740859","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1588"},{"key":"bibr4-1535370217740859","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)01307-0"},{"key":"bibr5-1535370217740859","first-page":"161","volume":"18","author":"Attal N.","year":"2012","journal-title":"Continuum"},{"key":"bibr6-1535370217740859","doi-asserted-by":"publisher","DOI":"10.1096\/fj.02-0211hyp"},{"key":"bibr7-1535370217740859","doi-asserted-by":"publisher","DOI":"10.2174\/187152811794776295"},{"key":"bibr8-1535370217740859","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2012.12.003"},{"key":"bibr9-1535370217740859","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000204184.34946.41"},{"key":"bibr10-1535370217740859","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-9-202"},{"key":"bibr11-1535370217740859","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.04.029"},{"key":"bibr12-1535370217740859","doi-asserted-by":"publisher","DOI":"10.1038\/nn1992"},{"key":"bibr13-1535370217740859","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2533"},{"key":"bibr14-1535370217740859","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharep.2015.06.010"},{"key":"bibr15-1535370217740859","first-page":"30313","volume":"10","author":"Zhang FF","year":"2016","journal-title":"Neurochem Int"},{"key":"bibr16-1535370217740859","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/961635"},{"key":"bibr17-1535370217740859","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2012.904"},{"key":"bibr18-1535370217740859","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(83)90201-4"},{"key":"bibr19-1535370217740859","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2010.3671"},{"key":"bibr20-1535370217740859","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2006.04.186"},{"key":"bibr21-1535370217740859","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2016.03.008"},{"key":"bibr22-1535370217740859","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2016.09.009"},{"key":"bibr23-1535370217740859","doi-asserted-by":"publisher","DOI":"10.3109\/10408448409029321"},{"key":"bibr24-1535370217740859","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.1991.71.5.1872"},{"key":"bibr25-1535370217740859","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0705891104"},{"key":"bibr26-1535370217740859","doi-asserted-by":"publisher","DOI":"10.1002\/lt.21810"},{"key":"bibr27-1535370217740859","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2008.73"},{"key":"bibr28-1535370217740859","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2012.00088"},{"key":"bibr29-1535370217740859","volume":"8","author":"Zhang Q","year":"2013","journal-title":"PLoS One"},{"key":"bibr30-1535370217740859","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2014.01.009"},{"key":"bibr31-1535370217740859","doi-asserted-by":"crossref","first-page":"514898","DOI":"10.1155\/2014\/514898","author":"Lin JQ","year":"2014","journal-title":"Evid Based Complement Alternat Med"},{"key":"bibr32-1535370217740859","doi-asserted-by":"publisher","DOI":"10.1186\/s12990-015-0012-7"},{"key":"bibr33-1535370217740859","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-18144-8_11"},{"key":"bibr34-1535370217740859","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-016-1842-z"},{"key":"bibr35-1535370217740859","volume":"6153215","author":"Qu YJ","year":"2016","journal-title":"Evid Based Complement Alternat Med"},{"key":"bibr36-1535370217740859","doi-asserted-by":"crossref","first-page":"8082753","DOI":"10.1155\/2016\/8082753","author":"Zhou J","year":"2016","journal-title":"Evid Based Complement Alternat Med"},{"key":"bibr37-1535370217740859","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2013.01.020"},{"key":"bibr38-1535370217740859","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1238-16.2016"},{"key":"bibr39-1535370217740859","doi-asserted-by":"publisher","DOI":"10.1002\/glia.20871"}],"container-title":["Experimental Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1535370217740859","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1535370217740859","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1535370217740859","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T17:49:37Z","timestamp":1777571377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ebm-journal.org\/journals\/experimental-biology-and-medicine\/articles\/10.1177\/1535370217740859\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,2]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1177\/1535370217740859"],"URL":"https:\/\/doi.org\/10.1177\/1535370217740859","relation":{},"ISSN":["1535-3702","1535-3699"],"issn-type":[{"value":"1535-3702","type":"print"},{"value":"1535-3699","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,2]]}}}